Fortrea, the Durham, North Carolina-based contract research organization (CRO), announced on October 19, 2026 that it has finished buying the Early Phase Services division of Worldwide Clinical Trials, a fellow Research Triangle CRO. The all-cash transaction, valued at approximately $45 million, brings Fortrea a clinical research unit (CRU) and a bioanalytical laboratory, both in Texas. The two companies first disclosed the agreement in early September, so the October announcement marks the deal’s completion rather than new terms.
“Completing this acquisition further strengthens our integrated, scalable and scientifically differentiated clinical development platform,” said Anshul Thakral, CEO of Fortrea. “This transaction demonstrates tangible progress in Fortrea’s return to growth as we invest in our ability to win new opportunities and create lasting value for clients.”
What Fortrea Bought
The acquired division includes three Texas sites. San Antonio is home to a 200-bed clinical pharmacology unit that operates under Good Clinical Practice (GCP) standards. Austin houses a 60,000-square-foot bioanalytical laboratory that meets Good Laboratory Practice (GLP) requirements, and Pflugerville has a biospecimen storage facility. According to Fortrea, the addition raises its early-phase capacity to more than 570 beds worldwide.
The bigger change may be the lab. The deal gives Fortrea in-house bioanalysis for both large and small molecules, so samples from its early-phase studies can be analyzed without leaving the company. Before the deal, Fortrea’s early clinical work ran through four CRUs in Dallas; Daytona Beach, Florida; Madison, Wisconsin; and Leeds, England.
Why Integration Is the Selling Point
Fortrea is pitching the combined business as a way to cut the operational handoffs between clinical sites and bioanalytical labs, which the company says should shorten turnaround times and make room for larger, more complex studies. Scott Dove, Ph.D., who joined Fortrea in January 2026 to lead the unit that now houses the Texas operations, put the rationale this way:
“With this investment, Fortrea adds capability and capacity in its commitment to help clients design and execute early development programs with greater speed, scientific rigor and operational connectivity,” said Dove, president, Clinical Pharmacology Services at Fortrea. “The addition of dedicated bioanalytical capabilities and expanded CRU capacity gives our teams more ways to support both simple and complex studies, streamline execution and generate high-quality data that inform development decisions.”
Thakral tied the purchase to client demand as well. “By bringing together complementary clinical pharmacology and bioanalytical capabilities, we expect to expand the speed, flexibility and talent we can offer clients as they advance increasingly complex development programs,” he said.
A Deal Between Triangle Neighbors
Both sides of this transaction are rooted in North Carolina. Fortrea has been headquartered in Durham since it spun out of Labcorp in 2023. Worldwide Clinical Trials is based at 600 Park Offices Drive in Research Triangle Park, according to the North Carolina Biotechnology Center directory. The leaders steering the integration also have Triangle CRO backgrounds. Thakral and Dove both previously held senior roles at PPD, according to their Fortrea biographies. Its significance for the region lies in how two Triangle-headquartered CROs are reshaping their businesses.
What Comes Next for Both Companies
The acquired operations now sit inside Fortrea’s Clinical Pharmacology Services business unit. Fortrea and Worldwide have signed agreements meant to keep ongoing studies, clients and employees on track during the transition, and the companies say they remain focused on avoiding disruption for study volunteers.
Worldwide is not leaving early development entirely. When the deal was announced, the company said it would keep supporting Phase I studies through its broader clinical development operations, and that proceeds would help it invest more heavily in late-stage services and expand its geographic reach. Barclays served as Fortrea’s financial advisor and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. served as its legal counsel.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.
